Japanese Poster Session

[Pj-052] Neuroimmunology (MS and disease modifying therapy2)

Thu. May 23, 2019 5:50 PM - 7:05 PM Poster Exhibition (Osaka International Convention Center 3F Event Hall)

Chair:Kyoichi Nomura(Department of Neurology, Saitama Medical Center, Saitama Medical University)

+Add all to schedule

[Pj-052-1] PML in a patient with multiple sclerosis treated with fingolimod: 2-year follow-up

Masahiro Mori¹, Shinji Aoyama², Akiyuki Uzawa¹, Tomohiko Uchida¹, Hiroki Masuda¹, Kyousuke Koide¹, Satoshi Kuwabara¹ (1.Department of Neurology, Graduate School of Medicine, Chiba University, 2.Chiba University School of Medicine)

[Pj-052-2] Death, infection and malignancy of multiple sclerosis disease modifying drug users from PMDA reports

Takayuki Kondo¹, Kyoko Nakata² (1.Kansai Medical University Medical Center, 2.Authorized non-profit organization MS Cabin)

[Pj-052-3] Safety and Effectiveness of Natalizumab Post-Marketing Surveillance: The 4th Year Interim Results

Takahiko Saida¹, Kazumasa Yokoyama², Ryusuke Sato³, Haruki Makioka³, Yukihiko Iizuka³, Nami Sugiyama³, Naoto Matsuda³, Shinichi Torii³ (1.Kansai Multiple Sclerosis Center, Kyoto Min-iren Central Hospital, 2.Department of Neurology, Juntendo University School of Medicine, 3.Biogen Japan Ltd)

[Pj-052-4] Clinical features of 24 multiple sclerosis patients treated with fingolimod and recurrent cases

Naohiko Iguchi, Takao Kiriyama, Nobuyuki Eura, Tesseki Izumi, Hiroshi Kataoka, Kazuma Sugie (Department of Neurology Nara Medical University)

[Pj-052-5] The disease course of multiple sclerosis without disease modifying drug

Katsuichi Miyamoto, Susumu Kusunoki (Department of Neurology, Kindai University School of Medicine)

[Pj-052-6] An observational study of the factors affecting adherence to glatiramer acetate in our MS patients

Masaki Iizuka, Akira Arakawa, Naoki Takegami, Syunichi Matuda, Toshihiro Yoshizawa (Department of Neurology, NTT Medical Center Tokyo)